RxDoctor Payments Data

Rashid Awan, MD

Anesthesiology · Corona, CANPI 1760011266

Payments from drug & device makers

$179in general payments, 2019–2025

Across 3 payments — averaging $59.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Revance Therapeutics, Inc.$179

What the payments were for

  • Food & beverage$179100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Revance Therapeutics, Inc.3$179

How this compares

$179 in reported general payments places this provider in the 60th percentile of 5,717 anesthesiology providers in California.

See all anesthesiology providers in California

Medicare billing

Part B allowed, 2024
$1,550,640
Medicare patients
6,810
Services billed
18,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$17,345
Ondansetron OdtOndansetron11$172

Paid to pharmacies, not to this prescriber.

Other anesthesiology in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →